ArticleJournal of hepatocellular carcinoma2026
Subgroup-Specific Nomogram for Refined Risk Stratification in Hepatocellular Carcinoma Patients with Low LDL-C.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) exhibits high mortality and clinical heterogeneity. While low low-density lipoprotein cholesterol (LDL-C) is a recognized risk factor for HCC, its continuous dose-response relationship with overall survival (OS) remains unclear. Furthermore, existing prognostic models lack precision for this specific high-risk population, highlighting an urgent need for individualized risk stratification. Methods: A retrospective cohort of 486 HCC patients treated at Beijing You'an Hospital (January 1, 2015-January 1, 2021) was analyzed. Restricted cubic splines (RCS) and Cox regression evaluated the LDL-C and OS dose-response relationship. Following quartile stratification (Q1-Q4), the cohort was dichotomized into low (Q1+Q2, n=245) and high (Q3+Q4, n=241) LDL-C groups. Within the high-risk low LDL-C subgroup, least absolute shrinkage and selection operator (LASSO) regression identified core features to construct a specific nomogram, validated via concordance index (C-index), receiver operating characteristic (ROC) curves, calibration, decision curve analysis (DCA), and Kaplan-Meier (KM) curves for risk stratification. Results: RCS analysis revealed a non-linear relationship: mortality risk increased as baseline LDL-C decreased below 2.2 mmol/L. Multivariable Cox regression confirmed LDL-C as an independent protective factor for OS (HR=0.714, 95% CI: 0.539-0.947, Conclusion: Lower baseline LDL-C is an independent predictor of worse OS. The developed subgroup-specific nomogram provides an objective tool for secondary risk stratification, aiding personalized therapeutic management for this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.